Exelixis Q2 revenue $469.8M, GAAP EPS $0.25; CABOMETYX drives growth

EXELIXIS, INC.

2023-Q2 EPS reported $0.37 revenue$878,636,000

Total revenues $469.8M (+12% YoY); net product revenues $409.6M (+18% YoY).
GAAP diluted EPS $0.25; non-GAAP diluted EPS $0.31, vs $0.22 and $0.28 last year.
CABOMETYX remains top TKI in RCC; growth driven by first-line combo with nivolumab.
Pipeline advances: zanzalintinib STELLAR-001 enrollment complete; XB002 dose selected.
Upcoming catalysts: CONTACT-02 readout, COSMIC-313 OS analysis, R&D Day Dec 12.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

EXELIXIS, INC. reported the quarter ended June 30, 2023 results: revenue Total revenues of $469.8 million, net income GAAP net income of $81.2 million, or $0.25 per share, EPS $0.25 per share.

Period: the quarter ended June 30, 2023
Revenue: Total revenues of $469.8 million
Net income: GAAP net income of $81.2 million, or $0.25 per share
EPS: $0.25 per share
Result: reported results

Exact text from the filing

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31

View on SEC.gov

Browse all earnings releases →

EXELIXIS, INC. filing history →

Source: SEC EDGAR

accession 0000939767-23-000078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.